ESTRO 2024 - Abstract Book

S1884

Clinical - Mixed sites, palliation

ESTRO 2024

Keywords: SABR, benign, cardiac arrhythmia

References:

1. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, Faddis M,Gleva M, Noheria A, Smith TW, Hallahan D, Rudy Y, Robinson CG. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med. 2017;377:2325 – 2336. doi: 10.1056/NEJMoa1613773 2. Lee J, Bates M, Shepherd E, Riley S, Henshaw,M Metherall P et al. Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience. Open Heart 2021;8:e001770. doi:10.1136/openhrt-2021-001770

1057

Digital Poster

Clinical efficacy of SBRT as adrenal gland metastasis-directed therapy in oligometastatic patients

Federico Colombo, Marco Galaverni, Cristina Dell'Anna, Elisabetta Lattanzi, Claudia Grondelli, Francesco Salaroli, Ilaria Renna, Stella Gianni, Giovanni Ceccon, Maria Luisa Bergamini, Nunziata D'Abbiero, Nicola Simoni

Azienda Ospedaliero-Universitaria di Parma, Radiation Oncology Unit, Parma, Italy

Purpose/Objective:

Adrenal gland metastases (AGMs) represent a common manifestation of metastatic tumor spread. In oligometastatic patients (OMPs), effective treatments for AGMs are needed. Aim of the present study was to evaluate the clinical efficacy of Stereotactic Body Radiotherapy (SBRT) as adrenal gland metastasis-directed therapy in OMPs.

Material/Methods:

Oligometastatic patients treated at our Institution with SBRT for AGMs were retrospectively analyzed. All patients were clinically and radiologically evaluated during and after completion of SBRT. Study endpoints were local progression-free survival (LPFS), disease free survival (DFS), overall survival (OS), and toxicity. Survival was estimated by the Kaplan-Meier method and factors potentially affecting outcomes were analyzed with Cox regression analysis.

Results:

From January 2017 to December 2022, 32 OMPs according to ESTRO-EORTC criteria, accounting for 35 AGMs, received SBRT as metastasis-directed therapy. Most AGMs originated from non-small cell lung cancers (71.9%). SBRT